A 40% year-over-year revenue decline for the former blockbuster drug Humira, due to direct biosimilar competition, is forcing a fundamental restructuring of the company's revenue portfolio.
Filing excerpt
Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qrestructuringGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/3f19def4-1fdd-48de-9274-141bb08319f7 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "3f19def4-1fdd-48de-9274-141bb08319f7",
"signal_type": "sec-10q",
"signal_subtype": "restructuring",
"detected_at": "2026-05-12T09:24:58.566+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "A 40% year-over-year revenue decline for the former blockbuster drug Humira, due to direct biosimilar competition, is forcing a fundamental restructuring of the company's revenue portfolio. This creates urgent needs for sales and marketing efficiency to accelerate a dozen growth products and find operational cost savings.",
"metrics": {
"pct": -0.4,
"timeframe": "current_quarter",
"pct_context": "Year-over-year decrease in Humira net revenues for the quarter"
},
"summary": "AbbVie's revenue base restructures as flagship drug Humira sees sales drop 40%",
"excerpts": "Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
"filing_date": "2026-05-08",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Change management needs",
"signal_category": "workforce"
}
}
curl https://signals.autobound.ai/v1/signals/3f19def4-1fdd-48de-9274-141bb08319f7 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.